Trillium Therapeutics Inc. (TRIL)

Oncology Corporate Profile

Stock Performance

11.6200
0.1500

3 Month Stock History Chart

HQ Location

96 Skyway Avenue
Toronto, Ontario, Canada M9W 4Y9

Company Description

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system.

Website: http://trilliumtherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TTI-621 (SIRPaFc)CD47 inhibitorVarious cancer typesI

Source: http://trilliumtherapeutics.com

Recent News Headlines

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/11/2017 12:20 am

8/11/2017 12:20 am

8/11/2017 12:20 am

8/11/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

6/28/2017 12:20 pm

6/28/2017 12:20 pm

6/28/2017 12:20 pm

6/28/2017 12:20 pm

6/7/2017 12:20 am

6/1/2017 12:20 pm

5/31/2017 12:20 am

Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

4/3/2017 11:00 am

[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following preclinical and clinical updates on its TTI-621 ...

Trillium Therapeutics to Present at Investor and Scientific Conferences in April

3/29/2017 11:00 am

[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the ...